Space Cargo Unlimited and Transcell Biologics Partner to Advance Drug Discovery in Space
Tran-Scell's CEO, Suba Dravida, with Space Cargo Unlimited Life Sciences Expert Avin Ramaiya
Transcell Biologics Private Limited (Transcell Biologics) and Space Cargo Unlimited have announced a strategic partnership to explore how research in microgravity could transform the way new medicines and vaccines are developed.
The collaboration brings together Transcell Biologics' expertise in human cell-based research and artificial intelligence with Space Cargo Unlimited's commercial microgravity research platform. Together, the companies will investigate whether the unique conditions of space can generate more predictive data on how potential treatments behave in the human body, helping researchers make better decisions earlier in the drug development process.
Today, only around one in ten drugs entering clinical trials ultimately reaches patients. Many fail because traditional preclinical models cannot fully replicate human biology. By combining human-relevant research with experiments in orbit, the partnership aims to improve the prediction of drug safety and effectiveness, reduce costly late-stage failures and support the growing move towards alternatives to animal testing.
Space Cargo Unlimited will provide the orbital research infrastructure, mission expertise and sample return capabilities, while Transcell Biologics will contribute its human microphysiological systems, artificial intelligence technologies, and expertise in human biology. The initial research will focus on areas including oncology, immunology, neurodegenerative disease, metabolic disorders, anti-ageing, and vaccine development.
Dr. Subhadra Dravida, Founder and Chief Executive Officer of Transcell Biologics, said: “Transcell Biologics is building the leading human biology intelligence stack. Microgravity broadens what our Solution can see. In orbit, tissue architecture, cellular organisation and immune signalling behave in ways not accessible at 1g. Space Cargo Unlimited makes that environment repeatedly available. Orbital data, read through our biology-driven AI, gives pharmaceutical partners a distinctly human-relevant layer of evidence for decisions across their pipelines.”
Nicolas Gaume, President of Space Cargo Unlimited, added: “This collaboration brings together two technologies with the potential to reshape how new therapies are developed. By combining Transcell Biologics' expertise in human biology and AI with Space Cargo Unlimited's proven capabilities in microgravity research, we have an opportunity to generate more predictive data that could transform preclinical drug development. We believe space is no longer just a destination for scientific discovery; it is becoming a powerful laboratory for innovation. Partnerships like this demonstrate how microgravity can help unlock new insights with real potential to improve human health.”
As interest grows in more predictive and human-relevant approaches to therapeutic development, the partnership aims to open new opportunities for pharmaceutical and biotechnology organisations to harness the unique research environment of space to accelerate the discovery of future medicines.